DOCSLIB.ORG

50 KW Offer Solar Copy 2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
50 KW Offer Solar Copy 2 21st Century Enviro Engineers Pvt.Ltd. Plot No. 120(10 Marla), COMPANY Industrial Area Phase II Chandigarh - 160002, India PROFILE www.21stcenturyenviro.com INTRODUCTION 21st CENTURY ENVIRO ENGINEERS PVT. LTD. is a Company dealing in the field of Environmental Engineering related activities. We are Registered Environmental Consultants of Pollution Control Board to Supply ETP’s, STP’s, APCD’s, Incinerators, Water Treatment Plants, Reverse Osmosis, Evaporators, Solid Waste Management and Rain Water Harvesting and to carry out EIA Studies . The Directors of the company are young Technocrats having versatile experience in this field. We have a back up of highly qualified and experienced technical team having versatile experience in Designing, Erection, Commissioning and Operation of different types of Effluent Treatment Plants. Our Managing Director himself is a Chemical Engineer with almost 25 Years Experience in this line and Technical Director is PhD. in Environmental Science with almost 30 Years working experience on various types of effluent treatment Technologies. Our team comprises of almost 150 people from different backgrounds e.g. Chemical, Environmental, Mechanical, Instrumentation, Civil, Accounts, Purchase, Marketing etc. We have our Marketing/ Design Office in Chandigarh and regional offices in Dhaka, Mumbai, New Delhi, Sikkim etc. and have our own testing Laboratory for Effluent/Water Testing and to study treatability of effluent on pilot scale. We have our own full-fledged manufacturing unit of Pollution Control Equipments in Village Kunjhal Baddi (HP). We also undertake annual operation and maintenance contracts and liasining services for the systems supplied by us. We are also Registered with CREST (Chandigarh Renewable Energy & Technology Promotion Society) and SECI (Solar Energy Corporation of India) for supplying Online/Offline Solar systems in Chandigarh, Himachal Pradesh, Uttarakhand, J&K, Punjab, Haryana, Delhi, Bihar etc. SERVICES PROVIDED • Consultancy to design Pollution Control Facilities • Turnkey Projects on Zero Discharge Effluent Treatment Plants • Turnkey Sewage Treatment Plants • Design and Supply of Incinerators • Environment Impact Assessment Studies • Environment Audits • Environmental Clearances • O & M Contracts for Pollution Control Facilities. • Rain Water Harvesting • Acoustic Enclosures for DG Sets • Technical Assistance to Get NOC/ Consent from Pollution Control Board • Trouble Shooting services in Environmental Engineering Field. • Solar Power Plants LABORATORY ANALYSIS Physical Tests: Colour, Conductivity, pH, Suspended solids, Settleable solids, Sludge Volume Index, Total solids, Temperature, Turbidity, Velocity & discharge measurement of industrial effluent stream, Fixed & volatile solids(FVS), Total dissolved solids, Odour. Chemical Tests: Acidity, Alkalinity, Arnmonical Nitrogen, Arsenic, Boron, Bromide, Chemical Oxygen Demand (COD), Bio-chemical Oxygen Demand (BOD), Chloride, Residual Chlorine, Calcium (Titrimetric), Chromium (Colorimetric), Dissolved Oxygen, Fluoride (Colorimetric without distillation), Hardness (Total), Iron (Colorimetric), Magnesium, Nickel, Nitrite- Nitrogen, Nitrate –Nitrogen, Oil and Grease (Simple extraction), Phosphate, Potassium, Sodium, Sulfide, Sulphate (Turbidimetric), Total dissolved solids (TDS), Cation Exchange Capacity (CEC), Nitrogen Available, Organic carbon / matter (Chemical method), Phosphorous Available, Phosphate(Ortho), Phosphate (Total), Potassium, SAR in soil Extract by calculation, Soil Moisture, Calorific value, Electrical Conductivity. TECHNOLOGIES AVAILABLE • UASB Based Anaerobic Treatment • Zero Discharge Effluent Treatment Plants • BioGas based Power Generation from Sewage • Sequential Batch Reactors • SAFF • FAB • MBBR • Conventional • MBR MAJOR TURNKEY ETP/STP/RO/EVAPORATOR INSTALLATIONS ñ UASB BASED BIOGAS POWER PLANT DERA SACHA SAUDA ñ UASB BASED BIOCNG (4216M3/D) PLANT DERA SACHA SAUDA ñ 8.0MLD SBR BASED STP PLANT PUNJAB WATER SUPPLY & SEWERAGE BOARD ñ 2.5MLD SBR BASED STP PLANT PUNJAB WATER SUPPLY & SEWERAGE BOARD ñ INCEPTA VACCINES LIMITED DHAKA ñ INCEPTA PHARMACEUTICALS LIMITED DHAKA ñ SQUARE PHARMA LIMITED PABNA BANGLADESH ñ PANACEA BIOTEC LTD(R&D) -ETP/STP ñ VIDEOCON INDUSTRIES LIMITED -ETP/STP ñ VIDEOCON INDUSTRIES LIMITED -ETP/STP ñ MICROLAB LIMITED - ETP/STP ñ MICROLAB LIMITED - ETP/STP ñ WATSON PHARMACEUTICALS LIMITED- ETP/STP ñ HPEL-MITTAL ENERGY LIMITED -STP ñ GODREJ CONSUMER CARE LTD -ETP/STP ñ JUBILIANT ORGANOSYS -ETP/STP ñ HIMALAYAN DRUGS LIMITED UASB BASED ETP ñ ANCHOR HEALTH AND BEAUTY PRODUCTS ETP/STP ñ GODREJ CONSUMER CARE LTD -ETP/STP ñ S.C.JOHNSON LIMITED -ETP/STP ñ RANBAXY LAB. LTD - RAIN WATER HARVESTING ñ RANBAXY LABORATORIES LIMITED -ETP/STP/RO ñ PANACEA BIOTEC LTD –ETP & STP ñ PANACEA BIOTEC LTD–ETP & STP OPERATION ñ PANACEA BIOTEC LTD(R&D) -ETP/STP ñ PANACEA BIOTEC LTD(FORMULATION) -ETP/STP ñ PANACEA BIOTEC LTD(FORMULATION) - ETP OPERATION ñ PANACEA BIOTEC LTD(VACCINE) -ETP ñ PANACEA BIOTEC LTD(FORMULATION) -INCINERATOR ñ PANACEA BIOTEC LTD LALRU –ETP/RO EXPANSION ñ GODREJ CONSUMER CARE LTD -ETP/STP ñ GODREJ CONSUMER CARE LTD -ETP OPERATION ñ GODREJ CONSUMER CARE LTD -ETP EXPANSION ñ GODREJ CONSUMER CARE LTD -ETP/STP ñ GODREJ CONSUMER CARE LTD -ETP OPEARTION ñ GODREJ HERSHEY FOODS & BEV. LTD -ETP/RO/EVAP ñ PROCTER & GAMBLE (MAPEX)-ETP/STP ñ PROCTER & GAMBLE (SARVOTHAM) -ETP/STP ñ PROCTER & GAMBLE (SARVOTHAM) –ETP OPERATION ñ PROCTER & GAMBLE LIMITED -RAIN WATER HARVESTING ñ PROCTER & GAMBLE LIMITED - HAZ. WASTE LANDFILL ñ PROCTER & GAMBLE LIMITED – FISH POND ñ VVF LIMITED -ETP/STP ñ VVF LIMITED -RAIN WATER HARVESTING ñ VVF LIMITED FATTY ACID PLANT- UASB BASED ETP PLANT ñ WIPRO LIMITED(TSP) -ETP/STP ñ WIPRO LIMITED(FATTY ACID -ETP ñ WIPRO LIMITED -ETP OPERATION ñ WIPRO LIMITED(LIGHTING)- STP ñ WIPRO LIMITED(LIGHTING) - APCD ñ HINDUSTAN LEVER LIMITED FATTY ACID PLANT-ETP ñ HINDUSTAN LEVER LIMITED FATTY ACID PLANT -RO ñ HINDUSTAN LEVER LIMITED FATTY ACID PLANT -EVAP ñ HINDUSTAN LEVER LIMITED FATTY ACID PLANT -INCINERATOR ñ HINDUSTAN KWALITY WALL-RAIN WATER HARVESTING ñ CIPLA LTD -ETP/STP ñ CIPLA LTD -ETP/STP OPERATION ñ CIPLA LTD -RAIN WATER HARVESTING ñ CIPLA LTD -RAIN WATER HARVESTING(COLONY) ñ CIPLA LTD -ETP EXPANSION ñ COLGATE PALMOLIVE(I) LTD -RAIN WATER HARVESTING ñ COLGATE PALMOLIVE(I) LTD –HAZ. WASTE LANDFILL ñ COLGATE PALMOLIVE(I) LTD –FISH POND ñ TVS MOTOR Co. -ETP ñ TVS MOTOR Co. - FILTER PRESS ñ TVS MOTOR Co. - ETP/STP/RO OPERATION ñ JOHNSON & JOHNSON LTD –ETP/STP ñ JOHNSON & JOHNSON LTD - RAIN WATER HARVESTING ñ JOHNSON & JOHNSON LTD – ETP OPERATION ñ DABUR PHARMA LIMITED -ETP/STP ñ DABUR PHARMA LIMITED -ETP OPERATION ñ DABUR PHARMA LIMITED- FISH POND ñ ADVANTEC COILS LIMITED UNIT1-STP ñ ADVANTEC COILS LIMITED-STP OPERATION ñ ADVANTEC COILS UNITII - ETP/STP/RO ñ PARABOLIC DRUGS LTD -INCINERATOR(25Kg/Hr) ñ PARABOLIC DRUGS LTD -INCINERATOR(200Kg/Hr) ñ PARABOLIC DRUGS LTD -ETP/STP ñ PARABOLIC DRUGS LTD -EVAPORATOR ñ MICROLAB LIMITED -ETP/STP ñ MICROLAB LIMITED -RAIN WATER HARVESTING ñ MICROLAB LIMITED -ETP OPERATION ñ JUBILIANT ORGANOSYS -ETP OPERATION ñ NECTAR LIFESCIENCES DERABASSI –ETP/STP ñ NECTAR LIFESCIENCES LALRU-ETP/STP ñ NECTAR LIFESCIENCES –RO ñ NECTAR LIFESCIENCES -EVAPORATOR ñ OZONE AYURVEDICS LIMITED -ETP/STP ñ OZONE PHARMACEUTICALS LIMITED-ETP/STP ñ BHARAT ELECTRONICS LTD -WATER SOFTNER ñ BHARAT ELECTRONICS LTD -WATER CHLORINATOR ñ FDC LIMITED -ETP/STP ñ FDC LIMITED-RAIN WATER HARVESTING ñ FIEYA VISION MACHINES CO PVT LTD -ETP/STP ñ FIEYA VISION MACHINES CO. –RAIN WATER HARVESTING ñ UNIMARCK PHARMA(I) LTD-ETP/STP ñ UNIMARCK PHARMA(I) LTD -ETP/STP ñ ISHAWAR MANUFACTURING-ETP/STP ñ ISHAWAR MANUFACTURING-ETP/STP ñ DR. REDDY’s LABORATORIES –ETP/STP ñ DEVYANI FOOD INDUSTRIES-ETP/STP ñ GLENMARK PHARMA LTD -ETP/STP ñ SHREYA LIFESCIENCES -ETP/STP ñ SOMANY TILES -ETP/STP ñ NATCO PHARMA -ETP/STP ñ TROIKAA PHARMA -ETP/STP ñ IPCA LABORATORIES LIMITED -ETP/STP ñ INTAS PHARMA. LIMITED -ETP/STP ñ CORAL LAB. LIMITED -ETP/STP ñ PHOENIX LAMPS LIMITED-ETP/STP ñ CADCHEM LABORATORIES LTD-ETP ñ CADCHEM LABORATORIES LTD-EVAPORATOR ñ CADCHEM LABORATORIES LTD-INCINERATOR ñ WALLACE PHARMACEUTICALS -ETP/STP ñ INDO FARM TRACTORS -ETP ñ YODEVA PLASTICS PVT. LIMITED-ETP/STP ñ CRIS PHARMA LIMTED -ETP/STP ñ PARAV BIOPHARMA PVT LTD-ETP/STP ñ INDAG RUBBER LIMITED-ETP/STP ñ UNIPATCH RUBBER LIMITED-STP ñ SUKAM POWER SYSTEMS LIMITED -ETP/STP ñ BHOJIA DENTAL COLLEGE -STP ñ HIMALAYAN INSTITUTE OF DENTAL SCIENCES -STP ñ BIRLA TYRES -ETP/STP ñ BIOLOGICAL E. LIMITED -ETP/STP ñ SIDMAK LABORATORIES PVT. LTD -ETP/STP ñ SHARON BIO-MEDICINES LIMITED-ETP/STP ñ SYNCOM HEALTHCARE LIMITED -ETP/STP ñ ANKUR DRUGS & PHARMA LIMITED-ETP/STP ñ VAIBHAV HEALTHCARE PVT.LTD -ETP/STP ñ SECURE METERS LIMITED -ETP/STP ñ ESSELL PROPACK - RAIN WATER HARVESTING ñ APAR INDUSTRIES LIMITED-STP ñ FIEM INDUSTRIES LIMITED-ETP & STP ñ VAPICARE PHARMA LIMITED-ETP/STP ñ KALINDI MEDICURE LIMITED-ETP/STP ñ SUPER HOSE INDUSTRIES-ETP/STP ñ OLIVE SOFTGEL -ETP/STP ñ SALUS PHARMA LTD -ETP/STP ñ GEM BATTERIES LTD -ETP/STP ñ PREET INTERNATIONAL -ETP/STP ñ ESS ESS BATHROOM PRODUCTS -ETP/STP ñ STEEL BIRD -ETP/STP ñ YASH INTERNATIONAL-ETP/STP ñ ESyS LIMITED -ETP/STP ñ MAGBRO HEALTHCARE LIMITED -ETP/STP ñ AMTEK AUTO LIMITED -ETP/STP ñ A.B.TOOLS LIMITED -STP ñ GILLETTE INDIA LIMITED - RAIN WATER HARVESTING ñ GREENPLY INDUSTRIES ñ ARISTO PHARMA LIMITED ñ BCC FUBA LIMITED-ETP/RO ñ ARISTO PHARMA LIMITED -ETP/STP/RO/RAINWATER HARVESTING ñ ARISTO LABORATORIES LIMITED -ETP/STP/RO ñ SARVOTHAM CARE LIMITED -ETP/STP ñ SURYA PHARMA LIMITED– INCINERATOR ñ DR. REDDY’s LABORATORY
Load more

Recommended publications
  • Replacements in Indices
    Date: February 21, 2018 PRESS RELEASE Replacements in Indices The Index Maintenance Sub-Committee (IMSC) has decided to make the following replacement of stocks in various indices as part of its periodic review. These changes shall become effective from April 02, 2018 (close of March 28, 2018). 1) NIFTY 50 The following companies are being excluded: Sr. No. Company Name Symbol 1 Ambuja Cements Ltd. AMBUJACEM 2 Aurobindo Pharma Ltd. AUROPHARMA 3 Bosch Ltd. BOSCHLTD The following companies are being included: Sr. No. Company Name Symbol 1 Bajaj Finserv Ltd. BAJAJFINSV 2 Grasim Industries Ltd. GRASIM 3 Titan Company Ltd. TITAN The above replacements will also be applicable to NIFTY50 Equal Weight Index. 2) NIFTY Next 50 The following companies are being excluded: Sr. No. Company Name Symbol 1 Bajaj Finserv Ltd. BAJAJFINSV 2 GlaxoSmithkline Consumer Healthcare Ltd. GSKCONS 3 Glaxosmithkline Pharmaceuticals Ltd. GLAXO 4 Glenmark Pharmaceuticals Ltd. GLENMARK 5 Tata Power Co. Ltd. TATAPOWER 6 Titan Company Ltd. TITAN 7 Torrent Pharmaceuticals Ltd. TORNTPHARM The following companies are being included: Sr. No. Company Name Symbol 1 Aditya Birla Capital Ltd. ABCAPITAL Sr. No. Company Name Symbol 2 Ambuja Cements Ltd. AMBUJACEM 3 Aurobindo Pharma Ltd. AUROPHARMA 4 Bosch Ltd. BOSCHLTD 5 General Insurance Corporation of India GICRE 6 L&T Finance Holdings Ltd. L&TFH 7 SBI Life Insurance Company Ltd. SBILIFE 3) NIFTY 500 The following companies are being excluded: Sr. No. Company Name Symbol 1 Adani Enterprises Ltd. ADANIENT 2 Ahluwalia Contracts (India) Ltd. AHLUCONT 3 Apar Industries Ltd. APARINDS 4 AstraZenca Pharma India Ltd. ASTRAZEN 5 Corporation Bank CORPBANK 6 Dalmia Bharat Ltd.
    [Show full text]
  • Glenmark Pharmaceuticals (GLEPHA)
    Glenmark Pharmaceuticals (GLEPHA) CMP: | 483 Target: | 560 (16%) Target Period: 12 months BUY August 17, 2020 Subdued topline; margin expansion to the fore… Revenues stayed flattish growing just 0.9% YoY to | 2345 crore due to subdued growth of 1.6% in US to | 743 crore, 3.7% growth in domestic sales to | 780 crore. Europe business grew 12.8% YoY to | 274 crore. RoW markets de-grew 18.1% YoY to 212 crore. EBITDA margins improved 567 bps YoY to 20.4% mainly due to lower other expenditure. EBITDA grew Particulars 39.8% YoY to | 478 crore. Adjusted PAT grew 106.9% YoY to | 226 crore. P articular Am ount Delta vis-à-vis EBITDA was due to higher other income. Exceptional items in Market Capitalisation | 13615 crore Q1FY21 were | 28 crore on gain arising from sale of Vwash brand to HUL. Debt (FY20) | 4868 crore Result Update Result Cash & equivalent (FY20) | 1111 crore US growth dependent on new launches E V | 17371 crore 52 week H/L (|) 573/168 US generics comprise ~30% of total revenues. So far, the company has E quity capital | 28.2 crore Face value | 1 received approval for 164 ANDAs while another 44 are pending approval, of which 24 are Para IV applications. However, Glenmark’s derma portfolio is Key Highlights facing stiff pricing pressure in the US. Going ahead, traction from the newly commissioned US based Monroe facility will be the key determinant besides Q1FY21 revenues remained flattish sustained product launches. We expect the US to grow at 5.2% CAGR in due to subdued US growth amid FY20-22E to | 3479 crore on the back of new launches.
    [Show full text]
  • Index Stock Update >> Marico Stock Update >> Gabriel India Stock Update >> PTC India Stock
    Visit us at www.sharekhan.com November 04, 2015 Index Stock Update >> Marico Stock Update >> Gabriel India Stock Update >> PTC India Stock Update >> Ipca Laboratories Stock Update >> Skipper Viewpoint >> Lloyd Electric & Engineering For Private Circulation only REGISTRATION DETAILS Regd Add: Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos. BSE - INB/INF011073351 ; BSE- CD ; NSE - INB/ INF231073330 ; CD-INE231073330 ; MSEI - INB/INF261073333 ; CD-INE261073330 ; DP - NSDL-IN-DP-NSDL-233-2003 ; CDSL-IN-DP-CDSL-271-2004 ; PMS- INP000000662 ; Mutual Fund-ARN 20669 ; Commodity trading through Sharekhan Commodities Pvt. Ltd.: MCX-10080 ; (MCX/TCM/CORP/0425) ; NCDEX- 00132 ; (NCDEX/TCM/CORP/0142) ; NCDEX SPOT-NCDEXSPOT/116/CO/11/20626 ; For any complaints email at [email protected] ; Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and Do’s & Don’ts by MCX & NCDEX and the T & C on www.sharekhan.com before investing. investor’s eye stock update Marico Reco: Buy Stock Update Enhanced focus to improve volume growth; maintain Buy CMP: Rs399 Company details Key points Price target: Rs460 Mixed operating performance: During Q2FY2016, Marico’s revenue grew by 4% to Rs1,485.4 crore, entirely driven by a 4% volume growth (domestic business’ volume Market cap: Rs25,735 cr growth stood at 5.5%). The gross profit margin (GPM) improved by almost 500BPS to 52 week high/low: Rs466/299 49.3% on the back of ~30% decline in the copra prices and 33% decline in the prices of liquid paraffin.
    [Show full text]
  • Hy Sun Missed the Pharma Rally: the Answer Is Hidden in a Bet Many Failed — Speciality Drugs - the Economic Times
    12/3/2020 Sun Pharma: Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs - The Economic Times Home ETPrime Markets News Industry RISE Politics Wealth MF Tech Jobs Opinion NRI Panache ET NOW More Aayush English Edition | E-Paper Tech Consumer Markets Corporate Governance Telecom + OTT Auto + Aviation Pharma Fintech + BFSI Economy Infra Environment Energy Business News › Prime › Pharma › Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs Getty Images MARKETS hy Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs Dilip Shanghvi, founder and managing director, Sun Pharmaceuticals Synopsis Sun Pharma is the only Indian company to have made some inroads into speciality drugs. What worries investors is high investments and uncertainties over ramp up in revenue. The stock can still see upside because of its current valuations, strong India business, and any positive surprises in US generic business. But it is crucial that its speciality bet pays off. BACK TO TOP https://economictimes.indiatimes.com/prime/pharma-and-healthcare/why-sun-missed-the-pharma-rally-the-answer-is-hidden-in-a-bet-many-failed-spe… 1/11 12/3/2020 Sun Pharma: Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs - The Economic Times Home ETPrime Markets NeCwasllI nitd uas trbyleRssISiEngP oilniti cdsisWgeuailthse fMoFr tTheceh InJodbisanOpinion NRI Panache ET NOW More pharmaceutical industry. The stocks of pharma companies have been on a tear since the beginning of the Covid-19 crisis.
    [Show full text]
  • DIA India ICH Day 2019 Enhancing Clinical Trial Outcomes with ICH 30Th August, 2019 | Taj Lands End | Mumbai, India
    DIA India ICH Day 2019 Enhancing Clinical Trial Outcomes with ICH 30th August, 2019 | Taj Lands End | Mumbai, India PROGRAMME COMMITTEE Today, the Indian pharmaceutical industry supplies approximately 20% of the world’s generic drugs and has the largest number of FDA-approved manufacturing facilities C. Michelle Limoli outside of the US. This industry has evolved during the past decade into innovative drug Senior International development, including new chemical and biological entities, biosimilars, and innovative Health Science Advisor differentiated products. At the same time, as healthcare costs continue to rise across the US FDA world, so does the global need for affordable, innovative healthcare. Against this backdrop, DIA India aims to create an initiative that will address the clinical and regulatory aspects Ramesh Jagannathan of drug development, through a comprehensive single day workshop on the latest ICH Associate Vice President guidelines and developments relevant for India. - R&D Biocon Ltd. Objective Anupama Ramkumar CEO and Principal The objective of this program is to provide a common platform for ICH trainers, regulatory Consultant authorities, academia, investigators, service providers, and the Indian biopharmaceutical Arkus Research Pvt. Ltd. industry, to deliberate upon and understand ICH guidelines and the most recent updates, impacting the drug development spectrum including key clinical, regulatory and quality Seema Pai aspects. Director - India Cluster Global Site & Study Take a look at our key topics for the event
    [Show full text]
  • Inner 25 India Pharma & Healthcare Fund
    Modera erate tely Mod High to e H w at ig o er h L d o M V e r y w H Tata India Pharma & Healthcare Fund o i L g (An open ended equity scheme investing in Pharma and Healthcare Services Sector) h Riskometer Investors understand that their principal As on 30th June 2021 PORTFOLIO will be at Very High Risk INVESTMENT STYLE Company name No. of Market Value % of Company name No. of Market Value % of Primarily focuses on investment in at least 80% of its net Shares Rs. Lakhs Assets Shares Rs. Lakhs Assets assets in equity/equity related instruments of the companies in the Pharma & Healthcare sectors in India. Equity & Equity Related Total 55184.24 97.88 Glenmark Pharmaceuticals Ltd. 167000 1089.76 1.93 INVESTMENT OBJECTIVE Healthcare Services Sanofi India Ltd. 13000 997.39 1.77 The investment objective of the scheme is to seek long Apollo Hospitals Enterprise Ltd. 70500 2551.99 4.53 Gland Pharma Ltd. 19662 673.29 1.19 term capital appreciation by investing atleast 80% of its Fortis Healthcare Ltd. 795000 1935.03 3.43 Laurus Labs Ltd. 90000 619.79 1.10 net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in Syngene International Ltd. 265000 1545.75 2.74 India.However, there is no assurance or guarantee that the investment objective of the Scheme will be Narayana Hrudayalaya Ltd. 301420 1483.74 2.63 Other Equities^ 1186.14 2.10 achieved.The Scheme does not assure or guarantee any Metropolis Healthcare Ltd.
    [Show full text]
  • Ipca Laboratories (IPCLAB)
    Ipca Laboratories (IPCLAB) CMP: | 2040 Target: | 2290 (12%) Target Period: 12 months HOLD May 31, 2021 Upbeat guidance, execution remains key Q4 revenues remained subdued growing just 3.8% YoY to | 1115 crore. Strong YoY growth of 19.7% in export formulations to | 338 crore was partly Particulars offset by API sales decline of 5.5% YoY to | 260 crore. Domestic Particular Amount formulations remained flat at | 434 crore vs. | 431 crore in Q4FY20. EBITDA Market Capitalisation | 25873 crore margins improved 484 bps YoY to 20.5% due to better gross margins and Debt (FY21) | 267 crore lower other expenditure. EBITDA grew 35.8% YoY to | 229 crore. PAT grew Cash (FY21) | 365 crore 87.5% YoY to | 161 crore (I-direct estimate: | 204 crore). Delta vis-à-vis EV | 25775 crore EBITDA was due to higher other income, lower depreciation and tax rate. 52 week H/L (|) 2456/1467 Equity capital | 25.4 crore Update Result Export formulations main catalyst for growth Face value | 2 Price performance Growth in export formulations (29% of FY21 revenues) was on the back of growth in both international generics and international branded 2500 14000 formulations. The international anti-malarial institutional business has also 12000 2000 contributed substantially to overall exports growth. US traction will take 10000 longer than earlier estimated due to USFDA import alerts for the Ratlam 1500 8000 facility that is the only API source for Silvassa and Pithampur formulations 1000 6000 plants along with Silvassa and Pithampur (Indore) plants that are specifically 4000 500 earmarked for the US business, besides third party sales.
    [Show full text]
  • Company Reliance Industries Limited Tata Consultancy Services
    Top 1000 Private Sector Companies (Rank-wise List) Company Reliance Industries Limited Tata Consultancy Services (TCS) Infosys Technologies Ltd Wipro Limited Bharti Tele-Ventures Limited ITC Limited Hindustan Lever Limited ICICI Bank Limited Housing Development Finance Corp. Ltd. TATA Steel Limited Ranbaxy Laboratories Limited HDFC Bank Ltd Tata Motors Limited Larsen & Toubro Limited (L&T) Satyam Computer Services Ltd. Maruti Udyog Limited Bajaj Auto Ltd. HCL Technologies Ltd. Hero Honda Motors Limited Hindalco Industries Ltd Reliance Energy Limited Grasim Industries Limited Jet Airways (India) Ltd. Sun Pharmaceuticals Industries Ltd Cipla Ltd. Gujarat Ambuja Cements Ltd. Videsh Sanchar Nigam Limited The Tata Power Company Limited Sterlite Industries (India) Ltd. Associated Cement Companies Ltd. Nestlé India Ltd. Hindustan Zinc Limited GlaxoSmithKline Pharmaceuticals Limited Siemens India Ltd. Motor Industries Company Limited Mahindra & Mahindra Limited UTI Bank Ltd. Zee Telefilms Limited Bharat Forge Limited ABB Limited i-Flex Solutions Ltd. Dr. Reddy's Laboratories Ltd. Nicholas Piramal India Limited Kotak Mahindra Bank Limited Reliance Capital Ltd. Ultra Tech Cement Ltd. Patni Computer Systems Ltd. Wockhardt Limited Indian Petrochemicals Corporation Limited Biocon India Limited Essar Oil Limited. Asian Paints Ltd. Dabur India Limited Jaiprakash Associates Limited JSW Steel Limited Tata Chemicals Limited Tata Tea Limited Tata Teleservices (Maharashtra) Limited The Indian Hotels Co. Ltd. Glenmark Pharmaceuticals Limited NIRMA Limited Jindal Steel & Power Ltd HCL Infosystems Ltd. Cadila Healthcare Limited Colgate-Palmolive (India) Limited The Great Eastern Shipping Company Limited Aventis Pharma India Ltd Ashok Leyland Limited Pantaloon Retail (India) Limited Indian Rayon And Industries Limited Financial Technologies (India) Ltd United Phosphorus Limited Matrix Laboratories Limited Sesa Goa Limited Lupin Ltd Cummins India Limited Crompton Greaves Limited.
    [Show full text]
  • Final Placement Report 2020-21
    FINAL PLACEMENT REPORT POST GRADUATE ProgrAM IN MANAGEMENT (PGP) 2019-21 12th BAtcH INDIAN INSTITUTE OF MANAGEMENT SHILLONG FOREWORD The Placement Committee of IIM Shillong takes immense pride in announcing the successful completion of the final placement season for the PGP batch of 2019-21. The stellar performance by the PGP participants stands testimony to the rapid progress made by IIM Shillong and has once again established IIM Shillong as the preferred choice for recruiters. We express our gratitude to our regular recruiters who have continuously believed in the mettle of our students and have furthered their association with us for another year to facilitate this mutually beneficial relationship. We are also grateful to our new recruiters, who have acknowledged the potential of our students and provided them with a plethora of opportunities. We appreciate the contribution of the entire IIM Shillong fraternity for their sustained assistance in the placement process. With continued support from students, recruiters, faculty, alumni, staff and management, we hope to carry this momentum onto the next academic year. Prof. Rohit Joshi Chairperson Placement Committee IIM Shillong BATCH PROFILE OF 2019-21 Education Background 9% 9% 9% 57% 198 16% Number 61% 39% of Students Male Female Engineering Arts Commerce & Finance Others Science Work Experience by Months Domain wise Work Experience Freshers 27% Information Technology & Analytics 47% 01-12 months 23% Consulting & Strategy 13% 19% Finance 23% 13-24 months 18% Sales & Marketing 11% 25-36
    [Show full text]
  • Stocks to Watch: Dish TV, Eicher, M&M
    Stocks to Watch: Dish TV, Eicher, M&M, Metropolis Health, Sun Pharma Friday, May 28, 2021 - Morning brief for the stock market: TOP EVENTS TODAY * Nifty 50 company detailing Jan-Mar earning: + Mahindra & Mahindra and Mahindra Vehicle Manufacturers, (Net profit seen 10.97 bln rupees vs 32.6 bln rupees loss year ago) * Jan-Mar earnings to be detailed by: 3M India, Incon Engineers, Rolcon Engineering Co, Action Construction Equipment, India Nippon Electricals, RSWM, AD Manum Finance, Indian Bank, Servoteach Industries, Aditya Birla Fashion and Retail, Indokem, Sharp Investments, Ador Multiproducts, IPCA Laboratories, Shish Industries, Ador Welding, ITD Cementation India, Shree Rama Newsprint, 1 Arvind Smartspaces, Jagran Prakashan, Shree Steel Wire Ropes, Associated Alcohols & Breweries, Jindal Poly Films, Shree Tulsi Online.Com, Aurionpro Solutions, Kama Holdings, Si Capital & Financial Services, Batliboi, Kanoria Chemicals & Industries, Sikozy Realtors, Bengal & Assam Co, Karur Vysya Bank, Sirca Paints India, Kovilpatti Lakshmi Roller Flour Blue Circle Services, SMS Pharmaceuticals, Mills, Lakshmi Electrical Control Bridge Securities, SRG Housing Finance, Systems, Calcom Vision, Max Healthcare Institute, SRU Steels, Camlin Fine Sciences, Mindteck India, Stanpacks India, Central Bank of India, Munoth Communication, Steel Exchange India, Chemo Pharma Laboratories, Munoth Financial Services, Steelcast, City Union Bank, NACL Industries, Sudal Industries, Classic Filaments, Navkar Corp, Sudarshan Chemical Industries, Confidence Futuristic Energetech,
    [Show full text]
  • In the United States District Court for the District of Delaware
    IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE NOVARTIS PHARMACEUTICALS CORPORATION Plaintiff, v. Civil Action No. _____ APOTEX INC., APOTEX CORP., BIONPHARMA INC., EMCURE PHARMACEUTICALS, HERITAGE PHARMACEUTICALS INC., EZRA VENTURES, LLC, GLENMARK PHARMACEUTICALS INC., USA, GLENMARK PHARMACEUTICALS LIMITED, HEC PHARM CO., LTD., HEC PHARM USA INC., HETERO USA INC., HETERO LABS LIMITED UNIT-V, HETERO LABS LIMITED, PRINSTON PHARMACEUTICAL INC., STRIDES GLOBAL PHARMA PRIVATE LIMITED, STRIDES PHARMA, INC., ZYDUS PHARMACEUTICALS (USA) INC., and CADILA HEALTHCARE LIMITED Defendants. COMPLAINT Novartis Pharmaceuticals Corporation (“Novartis”) by its attorneys hereby alleges as follows: NATURE OF THE ACTION 1. This is an action for patent infringement arising under the patent laws of the United States, Title 35, United States Code and for declaratory judgment pursuant to the Declaratory Judgment Act, 28 U.S.C. §§ 2201, et seq . This action relates to Abbreviated New Drug Applications (“ANDAs”) filed by the above-named defendants with the U.S. Food and Drug Administration (“FDA”) for approval to engage in the commercial manufacture, use, or sale of Fingolimod 0.5 mg capsules, generic versions of Novartis’s GILENYA ® Capsules, 0.5 mg, prior to expiration of U.S. Patent No. 10,543,179 (“the ’179 patent”). ME1 32500579v.1 PARTIES A. Novartis 2. Novartis Pharmaceuticals Corporation is a corporation organized and existing under the laws of the State of Delaware, with its principal place of business in East Hanover, New Jersey. B. The Generic Defendants a) Apotex Inc.; Apotex Corp. 3. Upon information and belief, Defendant Apotex Inc. is a corporation organized and existing under the laws of Canada, having a principal place of business at 150 Signet Drive, Toronto, Ontario, Canada M9L 1T9.
    [Show full text]
  • Cipla Limited
    Cipla Limited Registered Office: Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai – 400 013 Phone: (9122) 2482 6000, Fax: (9122) 2482 6893, Email: [email protected], Website: www.cipla.com Corporate Identity Number: L24239MH1935PLC002380 Annexure to the Board’s Report Particulars of employee remuneration for the financial year ended 31st March, 2017 As required under section 197(12) of the Companies Act, 2013, read with rule 5(2) and (3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014. Employed throughout the year Name Designation Qualification Experience Age Date of Last employment Remuneration (in years) (in years) Employment (`) Abhayan Jawaharlal CLO - International B.Com, LLB 18 45 03-09-2012 Biocon Group 12,009,351 Ajay Luharuka Head - IPD and API Finance B.Com, MMS, CFA 21 44 11-07-1996 NIIT Limited 12,800,997 Anil Kumar Kartha Site Head - Patalganga B. Sc., B. Pharm 26 54 27-05-1991 Vysali Pharmaceuticals 12,779,636 Anita S Desai Head - Formulations ADL B. Sc., PGCT 22 49 18-07-1994 Bombay Drug House 11,775,986 Anuj Aggarwal Regional Head - EU B. Tech., MBA 13 35 08-07-2013 Mckinsey & Company 13,664,962 Anupam Kashiv Head - Shared Services MPBSE 27 51 18-11-2013 Cadbury Business Services 27,837,834 Balwinder Singh Sethi Regional Head – MENA M.A 19 52 09-01-2012 Promed Exports Pvt Ltd 15,543,864 Chandru Chawla Global Head - CNV, Strategy and B. Tech., PG 29 51 12-12-2011 Lupin Limited 33,920,416 M&A Debashis Sarkar Head - Marketing and APAC DTM B.
    [Show full text]